Rotavirus vaccination: Issues & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI 2011-13 August 24 th & 25 th 2012.

Slides:

Advertisements

Similar presentations

25/8/2012 PERTUSSIS VACCINE FOR ADOLESCENTS CAN WE AFFORD TO BE COMPLACENT? YASH PAUL JAIPUR.

Advertisements

Module 4 Rotavirus vaccine administration

Module 3 Rotavirus vaccine eligibility

Module 3 Rotavirus vaccine eligibility

Training for rotavirus vaccine introduction Module 3 Rotavirus vaccine eligibility.

Objective of EBR related to IAPCOI 19 th February 2012, IMA House, New Delhi Vipin M. Vashishtha, MD, FIAP Convener,

Combined Veccination Against Hepatitis A & Hepatitis B The Rationale For a combine Hepatitis A/B Vaccine. Twinrix Twinrix is a vaccine which combines.

Feb 2011 Dr Guada Lopez Marti Pediatric Infectious Diseases Marshall University.

Implementing WA New State Exemption Requirements - Training for Schools and Child Cares/Preschools August XX, 2011 Preschool/Child Care Immunization Requirements.

Rotavirus vaccines Contentious issues and the way forward.

Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.

2011 Handbook Changes including “Catch Ups”. Outline Eligibility for Public Funded Vaccines Handbook Changes 2011 NIR and PMS Data Entry Planning Immunisation.

Adriana Weinberg, MD University of Colorado Denver.

Implementing WA New State Exemption Requirements - Training for Schools and Child Cares/Preschools August XX, 2011 Preschool/Child Care Immunization Requirements.

ACIP Meeting Update November 4 th

Typhoid vaccination: A curtain raiser & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI August 24 th &

19th VHPB meeting on "combined hepatitis B vaccines", Malta , Dr. M. Pfleiderer, PEI 1 European Regulatory Authorities´ Perspective and View.

 Definition of Immunization  Immunization Schedule  Success of Immunization Assessment of Success Factors Influencing Success  The Cold Chain.

School Based Immunization Campaign

Module 3 Inactivated poliovirus vaccine eligibility Training for Inactivated Poliovirus Vaccine (IPV) introduction.

Recommendations on IAP Immunization Time Table for 2012 Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI December 24 th, 25.

Welcome to the Immunization Requirements Webinar for Private Schools! For technical difficulties, call , press 1. During this webinar, everyone.

BCG complications.

ELIZABETH WILLIAMS, MD FELLOW IN VACCINOLOGY AND VACCINE SAFETY VANDERBILT UNIVERSITY AUGUST 30 TH, 2012 Thimerosal and Vaccine Safety.

Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.

Training for rotavirus vaccine introduction Module 3 Rotavirus vaccine eligibility.

Immunizations: 101 The Basics of Vaccine Administration

Protective effect of Natural ROTA virus infection A.J.Chitkara.

North Carolina Immunization Program: Basics & Beyond.

Survey of KAP of Pediatricians regarding Hib Disease & Vaccination in India during Pedicon Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI

Expanded Program of Immunization Dr. Faten M. Rabie.

Rotavirus vaccine coverage among a 2010 birth cohort and risk factors for partial or no coverage, Washington State 2010 K. Stigi, C. DeBolt, K. Lofy Washington.

Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.

Introduction of Hib in UIP Dr. Prashant P. Ghodam Moderator : Dr. Ranjan Solanki.

5th Annual Advocacy Project: ImmuneWise Section on Medical Students, Residents, and Fellowship Trainees

CDC’s Advisory Committee on Immunization Practices (ACIP) CDC’s Advisory Committee on Immunization Practices (ACIP) How is Vaccine Policy Made? William.

Combination vaccines (Presented by Dr. Shyama Saikia)

“Immunizations” What Parents Should Know. The Immune System DEFINITION: Body’s method of protecting itself from foreign substances that invade the body.

“Immunizations” What Parents Should Know Parenting Class.

VACCINE STORAGE AND ADMINISTRATION AMONG PRIMARY HEALTH CARE WORKERS IN SOUTH-EAST NIGERIA: EFFECT OF EDUCATIONAL INTERVENTION UZOCHUKWU BSC, ONWUJEKWE.

IAPCOI : Rollout plan Vipin M. Vashishtha, MD, FIAP Convener, July 16, 2011 IAP HQ, Mumbai.

PEDIATRIC VACCINE STOCKPILES A Status Report on the Pediatric Vaccine Stockpiles November 2005 Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Program Support.

TM OPV Stockpiling in the United States Trudy V. Murphy, M.D. National Immunization Program Centers for Disease Control and Prevention February 5, 2003.

ATR on the minutes of last meeting December 21 st 2012 Annual Meeting of IAPCOI, The City Park Hotel, NCR Delhi Vipin M. Vashishtha, MD, FIAP Convener,

Hepatitis A Issues and IAPCOI perspectives Dr Monjori Mitra Associate Professor Institute of Child Health Kolkata.

NEW CONCEPT OF NEW VACCINE. Airborne vaccine A. Varicella Vaccine:  Type: live attenuated vaccine.  Administration: 0.5 ml s.c  Immunity: 85%-90% for.

VFC Pediatric Vaccine Stockpile National Vaccine Advisory Committee October 23, 2007 Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Vaccine Supply and Assurance.

MANDATORY CHILDHOOD IMMUNIZATIONS AND ADOLESCENT HUMAN PAPILLOMAVIRUS (HPV): NO SHOTS – NO SCHOOL AUDREY MUNN AMY ROELSE.

Polio Research Activities in India Dr Sunil Bahl WHO-India, NPSP 15 March 2012.

The aims of immunisation: national policy & schedules.

INTRODUCTION TO INFORMATION SYSTEMS FOR IMMUNIZATION SERVICES IPV Global Workshop March 2014.

Hepatitis B immunization schedules in Europe Nicole Guérin Informations from WHO regional office site from VPD monitoring system 2000 and from personal.

Module 4 IPV vaccine administration Training for Inactivated Poliovirus Vaccine (IPV) introduction.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

Universal Vaccination Program Mexico: Lessons Learned from National Registry System November 2014.

Reasons for Incomplete Follow Up for HPV Vaccination in Females Attending an Urban Public Immunization Clinic Fiona G. Kouyoumdjian, 1 MD, MPH, CCFP, Anne.

Evaluation of the 2004 pneumococcal conjugate vaccine shortage utilizing data from the Michigan Childhood Immunization Registry Norma Allred, PhD, John.

We teach our kids to share… But sometimes they share more than they should…

Welcome to the Immunization Requirements Webinar for Clinic Staff! For technical difficulties, call , press 1. During this webinar, everyone.

Immunization of Preterm and Low Birth Weight Infants

Vaccine Efficacy, Effectiveness and Impact

Immunogenicity and Safety of a Combination Diphtheria, Tetanus Toxoid, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine Coadministered.

Fractional IPV (fIPV) eligibility

Module 8 Safety and acceptability of multiple injections

Safety and acceptability of multiple injections

Making the most of every immunization contact

Communicating with caregivers about IPV and multiple injections

Pertussis disease: regional perspectives

JE vaccine eligibility

Module 8 Safety and acceptability of multiple injections

Presentation transcript:

Rotavirus vaccination: Issues & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI August 24 th & 25 th 2012 Mid-term Meeting of IAPCOI, The Hyatt Regency Hotel, Mumbai

Issues: Individual protection: for office practice setting Public use: Mass use of RV vaccines through introduction in to NIP

I. Individual Protection:

Need to offer RV vaccine: Is there sufficient need? What hierarchy in relation to other routine pediatric vaccines?

Status of RV vaccine: What ought to be the relative status of RV vaccine in individual child’s immunization record? Vs Hib Vs IPV Vs PCV Vs acellular pertussis

How best to optimize performance of available RV vaccines in office setting? Issues to confront with: Type of vaccine? Number of doses? Schedule? Age restriction? Co-administration with OPV? Role of breast feeding? Recommendation on spitting/regurgitation?

Issues with RV1: Do we have ANY data on even immunogenicity of RV1 at 6, 10 weeks schedule in India? Are we justified in recommending TWO dose 6 & 10 weeks schedule even in suboptimal sero- conversion rates?

Immunogenicity of RV1:

II. Public use

Issues to confront with: Is there sufficient disease burden to merit mass vaccination? Are the available vaccines ‘potent’ enough to meet the challenge?

Are the available vaccines ‘potent’ enough? Adequate efficacy & effectiveness against RV disease What level of evidence do we have? Do we have ‘proper match’?

How to address the issue of poor efficacy of oral vaccines in India? Using higher potency ? Using more doses ? Use different schedule: late administration? Increasing interval between doses? Co-administration with other vaccines: ‘Separate’ with other oral vaccines? Use buffers? Issuing precaution regarding breastfeeding?

Are the available RV vaccines safe? Do we have background rates for IS? Do we have adequate PMS data on IS associated with RV vaccine use in India?

Issues with RV1 in India Do we have adequate data on efficacy of RV1 on 6, 10 week schedule? Need a demonstrative project on 2 Vs 3 doses of RV1 in India? Need to assess the potential benefits of a 3 rd dose of RV1 in India?

RV Vaccines: administration schedule Should all RV vaccine be used in a three or more-dose schedule? Should age-restriction on RV vaccines be removed?

Indian Rotavirus vaccine (116E) What is the current status of phase 3 trial? Any preliminary report on efficacy?

Cost-effectiveness of mass RV vaccination Is there any ongoing cost-effective analysis from India?

RV Vaccines: futuristic issues What is the pipeline for new RV vaccines? Role of a neonatal RV vaccine? Status of parenteral RV vaccine? Inactivated RV vaccines?